Trial reportCancer imaging : the official publication of the International Cancer Imaging Society2025
Transcatheter arterial chemoembolization with or without bevacizumab in hepatocellular carcinoma with portal vein invasion: a randomized trial.
Trial report in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with bevacizumab arterial perfusion compared to TACE alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT).
methodsIn this prospective, randomized, open-label, single-center study, 180 patients with HCC and PVTT were randomized (1:1) into a control group (TACE alone, n = 90) and an observation group (TACE plus bevacizumab, n = 90). Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included tumor response, changes in serum angiogenic factors (VEGF, PDGF), and tumor vascular density assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
resultsBaseline characteristics were well-matched. After a median follow-up of 24 months, the observation group showed significantly greater reductions in tumor diameter and number (P < 0.05). Post-treatment levels of VEGF and PDGF, and tumor vascular density, were significantly lower in the observation group (all P < 0.05). The median PFS was significantly longer in the observation group (10.5 months vs. 6.1 months; Hazard Ratio [HR], 0.58; P < 0.001), as was median OS (19.1 months vs. 13.0 months; HR, 0.62; P = 0.003). The incidence of grade ≥ 3 hypertension and thrombocytopenia was higher in the observation group (P < 0.05).
conclusionThis study suggests that adding bevacizumab to TACE is associated with improved tumor control, inhibition of angiogenesis, and significantly prolonged survival in patients with HCC and PVTT, with a manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.